You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.
The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.
Last year, the company processed more than 1 million tests, most of them for its reproductive health business, but interest in Prospera and Signatera is growing.
Several analysts said that the decision by UHC, the largest private payor in the US, will especially benefit Natera.
In a study involving 1,300 blood samples from pregnant women, Myriad researchers demonstrated that their method could increase the fetal fraction for almost all.
The company plans to show new data for its Signatera oncology test at three upcoming conferences this year, including in breast cancer and bladder cancer.
As a result of the expanded coverage, Natera said it believes there are currently 139 million people covered in the US for average risk NIPT.
For the half year ended Sept. 30, Yourgene booked £8.2 million ($10.7 million) in revenues, up from £7.8 million during the same period last year.
The deal includes UK-based Yourgene's test for detecting cancer patients who may have an adverse reaction to 5-fluorouracil, as well as reproductive health tests.
The company holds a leading position in reproductive testing and is expected to rapidly grow its oncology business to address a total market of $21 billion.